期刊
BLOOD ADVANCES
卷 6, 期 3, 页码 920-930出版社
ELSEVIER
关键词
-
类别
资金
- CIBMTR
- EBMT
- Public Health Service grant from the National Cancer Institute [U24CA076518]
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- Health Resources and Services Administration [HHSH250201700006C]
- Office of Naval Research [N00014-20-1-2705, N00014-20-1-2832]
- Be the Match Founda-tion
- Medical College of Wisconsin
- National Marrow Donor Program
- Actinium Phar-maceuticals
- ADIENNE
- AlloVir
- Amgen
- Angiocrine Bioscience
- Astellas Pharma US
- bluebird bio
- Bristol Myers Squibb
- Celgene
- CSL Behring
- CytoSen Therapeutics
- Daiichi Sankyo Company
- ExCellThera
- Fate Therapeutics
- Gamida Cell
- Genentech
- Incyte Corporation
- Janssen/Johnson Johnson
- Jazz Pharmaceuticals
- Kia-dis Pharma
- Kite
- Gilead Company
- Kyowa Kirin
- Legend Biotech
- Magenta Therapeutics
- Merck Sharp Dohme
- Millennium
- Takeda Oncology
- Miltenyi Biotec
- Novartis Pharmaceuticals
- Omeros
- OncoImmune
- Orca Biosystems
- Pfizer
- Pharmacyclics
- Sanofi Gen-zyme
- StemCyte
- Takeda Pharma
- Vor Biopharma
- Xenikos BV
This study evaluated the outcomes of different types of allo-HCT in mature T-cell lymphomas and found no significant differences in survival and progression between the different groups. Results suggest that haplo-HCT can be comparable to matched sibling donor HCT.
Mature T-cell lymphomas constitute the most common indication for allogeneic hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative to commonly used donor sources are not available. Included in this registry study were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) between 2008 and 2018. Hematopoietic cell transplantation (HCT) platforms compared were posttransplant cyclophosphamidebased haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched unrelated donor HCT with in vivo T-cell depletion (MUD TCD+), and matched unrelated donor HCT without in vivo T-cell depletion (MUD TCD-). Coprimary end points were overall survival (OS) and progression-free survival (PFS); secondary end points included nonrelapse mortality (NRM), and relapse/progression incidence (RI). A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD+; 326 MUD TCD-). Cohorts were comparable for baseline characteristics with the exception of higher proportions of patients with decreased performance status (PS) and marrow graft recipients in the haplo-HCT group. Using univariate and multivariate comparisons, OS, PFS, RI, and NRM were not significantly different among the haplo-HCT, MSD, MUD TCD+, and MUD TCD- cohorts, with 3-year OS and PFS of 60%, 63%, 59%, and 64%, respectively, and 50%, 50%, 48%, and 52%, respectively. Significant predictors of inferior OS and PFS on multivariate analysis were active disease status at HCT and decreased PS. AITL was associated with significantly reduced relapse risk and better PFS compared with PTCL-NOS. Allo-HCT can provide durable PFS in patients with mature T-cell lymphoma (TCL). Outcomes of haplo-HCT were comparable to those of matched donor allo-HCT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据